ARD-101
Phase 3Active 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Hyperphagia
Conditions
Hyperphagia, Prader-Willi Syndrome, Hyperphagia in Prader-Willi Syndrome
Trial Timeline
Jul 23, 2024 → Apr 1, 2027
NCT ID
NCT07197034About ARD-101
ARD-101 is a phase 3 stage product being developed by Aardvark Therapeutics for Hyperphagia. The current trial status is active. This product is registered under clinical trial identifier NCT07197034. Target conditions include Hyperphagia, Prader-Willi Syndrome, Hyperphagia in Prader-Willi Syndrome.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07197034 | Phase 3 | Active |
| NCT05153434 | Phase 2 | Completed |
| NCT05215847 | Phase 2 | Completed |
Competing Products
3 competing products in Hyperphagia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Carbetocin | Acadia Pharmaceuticals | Phase 3 | 72 |
| Carbetocin + Placebo | Acadia Pharmaceuticals | Phase 3 | 72 |
| Placebo + ARD-101 | Aardvark Therapeutics | Phase 3 | 69 |